Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Cocoa Prices Undercut Amid the Prospects of Abundant Supplies - 2Mali and Canadian miner Barrick agree to resolve tax dispute, ending 2-year standoff
- 3Flu surges across U.S. as doctor visits reach highest level since 1997
- 4Hungary's 'water guardian' farmers fight back against desertification
- 5This widow influencer is using jokes to cope after her husband's death. It's OK if people don't get it.
- Hamas delegation meets Egypt’s spy chief amid mutual ceasefire violation claims
- A Manual for Pick Viable Psychological well-being Backing Administrations In 2024
- Influencers are selling a delusional fantasy of being postpartum. Why is it so easy to believe?
- Catholic influencer shares death of 5-year-old son from 'severe' flu
- Transform the daily grind to make life more interesting – a philosopher shares 3 strategies to help you attain the good life
- From Specialist to Proficient Picture taker: Individual Triumphs
- Vote In favor of Your #1 Method for diminishing Pressure
- Full Supreme Court to hear challenge to Judicial Selection Committee law
- Most loved Specially prepared Espresso Mix: Which Meal Do You Adore the Most?
